Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MEDI3902 in healthy adults
NCT02255760Phase 1Completed
- Sponsor
- MedImmune
- Start
- Sep 2014
- Primary completion
- Apr 2015
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gremubamab in Pseudomonas aeruginosa pneumonia (5 arms), sponsored by MedImmune. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Number of Participants With Treatment-Emergent Serious Adverse Events and Adverse Events of Special Interest and 2 more. Started Sep 2014; status: completed.
02
Drugs
gremubamab
03
Conditions
Pseudomonas aeruginosa pneumonia
Beyond the preview
Go deeper on NCT02255760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255760.